Pharmafile Logo
Pharmafocus logo
Advanced Search

Sanofi

Showing 15 posts of 579 posts found.

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria

September 26, 2025
Research and Development Dupixent, Regeneron, Sanofi, urticaria

Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human …

News

Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition

August 14, 2025
Medical Communications, Research and Development European Alliance of Associations for Rheumatology, European Medicines Agency, IgG4-related disease, Rheumatology, Sanofi

The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) inhibitor, rilzabrutinib, for the treatment …

News
sanofi

Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline

August 6, 2025
Mergers and Acquisitions Alzheimer's disease, Corporate, Neurology, Sanofi, Vigil Neuroscience, neurodegenerative diseases

Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology company specialising in neurodegenerative diseases. …

News
blood-1813410_960_720

FDA grants orphan drug designation to relapsed or refractory multiple myeloma candidate

August 6, 2025
Medical Communications, Research and Development Oncology, Sanofi, US Food and Drug Administration, myeloma

The US Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, Sanofi’s investigational monoclonal antibody developed for …

News
europe-1395916_640

Sanofi’s Sarclisa gains EU approval for multiple myeloma treatment

July 30, 2025
Medical Communications, Research and Development European Commission, Oncology, Sanofi, Sarclisa, european union, multiple myeloma

Sanofi has received approval from the European Commission for the use of Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and …

News
Photo of patient

FDA grants orphan drug designation to antibody-mediated rejection treatment

June 26, 2025
Research and Development FDA, Immunology, Orphan Drug Designation, Sanofi, antibody-mediated rejection, clinical trials, immunology, inflammation, organ transplantation

Sanofi has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to riliprubart for …

News

Sarclisa recommended for EU approval in newly diagnosed multiple myeloma

June 24, 2025
Research and Development Committee for Medicinal Products for Human USE, EU, European Commission, European Medicines Agency, German-speaking Myeloma Multicenter Group, Oncology, Sanofi, blood cancer, monoclonal antibody

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended Sanofi’s Sarclisa (isatuximab) for approval in …

News
clinical_trials

Dupixent improves symptoms in patients with skin of colour, study shows

June 11, 2025
Advocacy Development, Medical Education, Research and Development Dermatology, Dupixent, Regeneron, Sanofi, atopic dermatitis, dermatology, underserved populations

Sanofi and Regeneron have announced results from the collaborative phase 4 DISCOVER study, presented at the Revolutionizing Atopic Dermatitis Conference, …

News
handshake

Sanofi to acquire Blueprint, advancing therapy for rare immunological diseases

June 3, 2025
Mergers and Acquisitions, Research and Development Blueprint Medicines, Immunology, Rare Diseases, Sanofi, advanced systemic mastocytosis (ASM), indolent systemic mastocytosis (ISM), rare immunological diseases

Sanofi and Blueprint Medicines Corporation, a US biopharma, have entered into an agreement under which Sanofi will acquire Blueprint. This …

News

Teen band 1Type releases single to raise awareness of type 1 diabetes

May 30, 2025
Medical Communications, Medical Education 1Type, Diabetes, Rise Up, Sanofi, Stagecoach Performing Art, autoimmune type 1 diabetes

Four teenagers living with autoimmune type 1 diabetes (aT1D) have released a single aimed at raising awareness of the condition …

News
handshake

Sanofi to acquire Vigil Neuroscience, adding Alzheimer’s disease candidate to early-stage pipeline

May 23, 2025
Mergers and Acquisitions, Research and Development Alzheimer's disease, Neurology, Sanofi, Vigil Neuroscience, neurodegenerative diseases

Sanofi has announced an agreement to acquire Vigil Neuroscience, a biotech company focused on therapies for neurodegenerative diseases. The deal …

News

Sanofi and CD&R finalise Opella deal, launching global consumer healthcare giant

May 6, 2025
Mergers and Acquisitions (OTC & VMS), Clayton, Clayton Dubilier & Rice (CD&R), Corporate, M&A, Opella, Sanofi, agreement

Sanofi and Clayton, Dubilier & Rice (CD&R) have officially closed the sale of a controlling 50% stake in Opella, Sanofi’s …

News
blood-75301_640

Sobi and Sanofi’s Foundation S renew partnership with World Federation of Hemophilia

April 28, 2025
Pharmacy sales & educational programmes, Sales and Marketing Haematology, Sanofi, World Federation of Hemophilia, bleeding disorder, sobi

Sobi and Sanofi, through its organisation Foundation S, have extended their partnership with the World Federation of Hemophilia (WFH) Humanitarian …

News

Dupixent approved as first biologic medicine in Japan for COPD patients

April 2, 2025
Research and Development COPD, Chronic Diseases, Regeneron, Sanofi, biotech, respiratory disease

The Ministry of Health, Labour and Welfare in Japan has authorised marketing and manufacturing of Dupixent (dupilumab) for the treatment …

News

Qfitlia approved by FDA to treat haemophilia A or B

March 31, 2025
Research and Development FDA, Haematology, Sanofi, haemophilia, pharma

The US Food and Drug Administration (FDA) has approved Qfitlia (fitusiran) as the first therapy in the US to treat …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025